EP1778857A4 - Activation directe de l'atiii dans le sang total et le plasma - Google Patents

Activation directe de l'atiii dans le sang total et le plasma

Info

Publication number
EP1778857A4
EP1778857A4 EP05769136A EP05769136A EP1778857A4 EP 1778857 A4 EP1778857 A4 EP 1778857A4 EP 05769136 A EP05769136 A EP 05769136A EP 05769136 A EP05769136 A EP 05769136A EP 1778857 A4 EP1778857 A4 EP 1778857A4
Authority
EP
European Patent Office
Prior art keywords
atiii
plasma
direct activation
full blood
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05769136A
Other languages
German (de)
English (en)
Other versions
EP1778857A1 (fr
Inventor
David R Elmaleh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1778857A1 publication Critical patent/EP1778857A1/fr
Publication of EP1778857A4 publication Critical patent/EP1778857A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18Testing for antimicrobial activity of a material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81Protease inhibitors
    • G01N2333/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121Serpins
    • G01N2333/8128Antithrombin III
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
EP05769136A 2004-07-07 2005-07-07 Activation directe de l'atiii dans le sang total et le plasma Withdrawn EP1778857A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58604304P 2004-07-07 2004-07-07
PCT/US2005/024046 WO2006014519A1 (fr) 2004-07-07 2005-07-07 Activation directe de l'atiii dans le sang total et le plasma

Publications (2)

Publication Number Publication Date
EP1778857A1 EP1778857A1 (fr) 2007-05-02
EP1778857A4 true EP1778857A4 (fr) 2007-09-26

Family

ID=35787415

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05769136A Withdrawn EP1778857A4 (fr) 2004-07-07 2005-07-07 Activation directe de l'atiii dans le sang total et le plasma

Country Status (6)

Country Link
EP (1) EP1778857A4 (fr)
JP (1) JP2008505912A (fr)
CN (1) CN101014717A (fr)
AU (1) AU2005269887A1 (fr)
CA (1) CA2576173A1 (fr)
WO (1) WO2006014519A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
EP1597978A1 (fr) 2004-05-17 2005-11-23 Nutricia N.V. Synergie de GOS et polyfructose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
EP1721611A1 (fr) * 2005-04-21 2006-11-15 N.V. Nutricia Supplément nutritionnel avec des oligosaccharides pour une catégorie de patients avec HIV
WO2008100258A1 (fr) * 2007-02-14 2008-08-21 Academic Medical Center, University Of Amsterdam Administration intrapéritonéale d'antithrobmine iii, compositions et procédés associés
CN101684646B (zh) * 2008-09-27 2011-03-23 海洋石油工程股份有限公司 可调节高度的垫墩
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058638A2 (fr) * 2001-01-26 2002-08-01 The General Hospital Corporation Medicaments a base de serpine pour le traitement de l'infection par vih et utilisation de ceux-ci
WO2004100973A2 (fr) * 2003-05-13 2004-11-25 The General Hospital Corporation Compositions pharmaceutiques d'antithrombine iii destinees au traitement de maladies a retrovirus.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058638A2 (fr) * 2001-01-26 2002-08-01 The General Hospital Corporation Medicaments a base de serpine pour le traitement de l'infection par vih et utilisation de ceux-ci
WO2004100973A2 (fr) * 2003-05-13 2004-11-25 The General Hospital Corporation Compositions pharmaceutiques d'antithrombine iii destinees au traitement de maladies a retrovirus.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COOMBE D R ET AL: "LOW ANTICOAGULANT HEPARIN RETAINS ANTI-HIV TYPE 1 ACTIVITY IN VITRO", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 11, no. 11, 1995, pages 1393 - 1396, XP009033624, ISSN: 0889-2229 *
GEIBEN-LYNN RALF ET AL: "Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 44, 1 November 2002 (2002-11-01), pages 42352 - 42357, XP002288481, ISSN: 0021-9258 *
See also references of WO2006014519A1 *

Also Published As

Publication number Publication date
CA2576173A1 (fr) 2006-02-09
CN101014717A (zh) 2007-08-08
WO2006014519A1 (fr) 2006-02-09
JP2008505912A (ja) 2008-02-28
EP1778857A1 (fr) 2007-05-02
AU2005269887A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
DE60327203D1 (de) Kombination von azelastine und fluticasone
DE602004032140D1 (de) Behandlungsvorrichtung mit verwendung von ausgangsstoffgas und reaktivem gas
DE60319925D1 (de) Verringerung des Ausflusses von Partikeln in Bohrlöchern
EP1551324A4 (fr) Ensembles de traitement de fluides et dispositifs de commande destines a ceux-ci
ATE486091T1 (de) Vegf-fallen und therapeutische verwendungen dafür
IL181779A (en) A group of protein-based medical molecules
EP1855833A4 (fr) Plasmas et procedes d'utilisation
DE602005017456D1 (de) Plasma-Anzeigetafel und Herstellungsverfahren derselben
DE602005027825D1 (de) Als inhibitoren von jak und anderen proteinkinasen geeignete azaindole
DE602005007494D1 (de) Azaindolinhibitoren von mtp und apob
DE60328206D1 (de) Scheibenwaschanlagendüse und scheibenwaschanlage
DE602005021589D1 (de) Mehrachsiger Drucksensor-Chip und mehrachsiger Drucksensor damit
EP1511736A4 (fr) Molecules therapeutiques et procedes - 1
EP1746902A4 (fr) Chromatographie d'affinite multi-lectine et ses utilisations
DE60325158D1 (de) Turbomolekularpumpe und Flansch
DE60325967D1 (de) Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen
DE602005022926D1 (de) Wärmeerhöhung bei kritischem sichtbereich von transparenter kunststofftafel
DE10338270B4 (de) Variator und Variatoranordnung
ATE524183T1 (de) Verwendung von sanglifehrin bei der hcv-therapie
EP1738654A4 (fr) Solution et gel contenant une proteine de soja
EP1778857A4 (fr) Activation directe de l'atiii dans le sang total et le plasma
ATE420081T1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
PL377180A1 (pl) Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
DE602005022211D1 (de) Sieb und sichter mit siebbruchdetektor
IL177435A0 (en) Expression of plasminogen and microplasminogen in duckweed

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20070829

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20071220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100202